logo
‘Could become a death spiral': scientists discover what's driving record die-offs of US honeybees

‘Could become a death spiral': scientists discover what's driving record die-offs of US honeybees

The Guardian08-07-2025
Bret Adee is one of the largest beekeepers in the US, with 2 billion bees across 55,000 hives. The business has been in his family since the 1930s, and sends truckloads of bees across the country from South Dakota, pollinating crops such as almonds, onions, watermelons and cucumbers.
Last December, his bees were wintering in California when the weather turned cold. Bees grouped on top of hives trying to keep warm. 'Every time I went out to the beehive there were less and less,' says Adee. 'Then a week later, there'd be more dead ones to pick up … every week there is attrition, just continually going down.'
Adee went on to lose 75% of his bees. 'It's almost depressingly sad,' he says. 'If we have a similar situation this year – I sure hope we don't – then we're in a death spiral.'
It developed into the largest US honeybee die-off on record, with beekeepers losing on average 60% of their colonies, at a cost of $600m (£440m).
Scientists have been scrambling to discover what happened; now the culprits are emerging. A research paper published by the US Department of Agriculture (USDA), though not yet peer-reviewed, has found nearly all colonies had contracted a bee virus spread by parasitic mites that appear to have developed resistance to the main chemicals used to control them.
Varroa mites – equivalent in size to a dinner plate on a human body – crawl and jump between worker bees. If there are no infections present, they do not typically damage the bee. But if diseases are present, they quickly spread them.
While varroa typically infects honeybees, not wild bees, the diseases that they spread can kill other pollinators – research has shown that the viral outbreaks among honeybees often spill over to wild colonies, with potential knock-on effects on biodiversity.
All beekeepers in the USDA screening used amitraz, a pesticide widely used in the sector to get rid of mites. But the research showed all mites tested were resistant to it: after years of heavy use, amitraz no longer appears to be effective. This discovery underscores 'the urgent need for new control strategies for this parasite', researchers say.
Mite numbers have increased to high levels in recent surveys, according to the researchers, who collected hundreds of samples from dead and living hives from 113 colonies. 'When mites become uncontrolled, virulent viruses are more likely to take over,' researchers say.
Since the 1980s, varroa mites globally have developed resistance to at least four leading miticides – pesticides specifically formulated to control mites that are challenging to develop – causing significant problems for beekeepers.
Norman Carreck, a senior technician at the University of Sussex, who was not involved in the research, says: 'Sadly, it was inevitable that major honeybee colony losses would again occur in the US at some point.
'It was only a matter of time before widespread resistance to amitraz, the only remaining effective synthetic chemical, would develop,' he says.
But the discovery of amitraz-resistant mites in hives does not mean they alone were responsible for all of last year's record die-offs. A combination of factors is likely to be causing successive colony deaths among US bees, including the changing climate, exposure to pesticides, and less food in the form of pollen and nectar as monocrop farming proliferates. Many US beekeepers now expect to lose 30% of their colony or more every year.
These wider combined factors are also devastating for wild pollinators and native bee species – and honeybees, which are closely monitored by their keepers, may be acting as a canary in the coalmine for pressures affecting insects more generally.
Paul Hetherington, of the charity Buglife, says honeybees are in effect 'a farmed animal as opposed to wild bees, but they will be suffering from the same stresses as their wild cousins, in particular loss of good habitat, climate stress, chemical stress, light.
Adee says: 'We had mites for 20 years, and we never had over 3% losses.' He believes there is a 'combination of things' that makes the bees more stressed and the mites more deadly.
He cites the use of neonicotinoid insecticides in the US, which harm bees' nervous system, paralysing and ultimately killing them. Some researchers have warned of neonicotinoids causing another 'silent spring', referring to Rachel Carson's 1962 book on the effects of the insecticide DDT on bird populations.
Dave Goulson, professor of biology at the University of Sussex, says the study provided no evidence that the viral load was higher in weaker colonies. 'Almost all bee colonies have these viruses, but they only do significant harm when the colony is stressed.'
He says high levels of viral infection may be a symptom of ill health, not the cause.
Due to government staffing cuts, the USDA team were unable to analyse pesticides in the hives and asked bee experts at Cornell University to carry out the research, with the results still to be published.
Experts are concerned that successive loss of honeybee colonies could affect food security as the insects pollinate more than 100 commercial crops across North America. Reports of new losses this year came through before the California almond blossom season, which is the largest pollination event in the world, requiring the services of 70% of US honeybees.
Danielle Downey, director of the nonprofit beekeeping research organisation Project Apis m., which conducted the die-off survey, says: 'If you like to eat, you need healthy bees to pollinate crops. Beekeepers try to rebuild each year but they are pushed to the brink as losses and input costs keep increasing.
'If beekeepers fail, there is no backup plan for the pollination services they provide in US food production,' she says.
Meanwhile, beekeepers are being pushed close to ruin. When Adee was growing up, he would get upset about losses of more than 5%. Now a loss of 30% each year is standard. 'It's absolutely insane that that's an acceptable loss in a livestock industry,' he says.
Like many beekeepers, Adee was unable to restock this year because the losses were so high. 'I'm just watching every nickel and dime right now, because I don't want to get rid of men that have helped me manage these bees for years.'
Find more age of extinction coverage here, and follow the biodiversity reporters Phoebe Weston and Patrick Greenfield in the Guardian app for more nature coverage
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Undeclared milk leads to US-wide butter recall
Undeclared milk leads to US-wide butter recall

The Independent

time41 minutes ago

  • The Independent

Undeclared milk leads to US-wide butter recall

A voluntary recall has been issued for over 64,000 pounds of Bunge North America's NH European Style Butter Blend due to undeclared milk, a common allergen. The recall was initiated on 14 July and classified as a Class II recall by the FDA. The affected butter was distributed to 12 US centres and one in the Dominican Republic. This butter recall is part of a series of recent food and drink issues, including High Noon Vodka Seltzer being recalled as it was mislabeled as non-alcoholic energy drinks. Consumers are advised to check affected products and dispose of or return them.

Might a combination of 2 cancer drugs help treat Alzheimer's disease?
Might a combination of 2 cancer drugs help treat Alzheimer's disease?

Medical News Today

time5 hours ago

  • Medical News Today

Might a combination of 2 cancer drugs help treat Alzheimer's disease?

Researchers are actively seeking treatments or a cure for Alzheimer's diseaseOne current research avenue is to look at currently-approved medications that are used for other diseases, an approach that is called drug repurposing. A new study has identified two cancer medications that may help overturn brain changes caused by Alzheimer's disease, possibly slowing or even reversing the disease's symptoms. Researchers all over the world are actively seeking treatments or a cure for Alzheimer's disease — a form of dementia currently impacting about 32 million people globally. The medications used right now for Alzheimer's disease are designed to only help treat symptoms and slow disease progression. One avenue scientists are taking in an effort to find treatments for Alzheimer's disease is by looking at currently-approved medications that are used for other diseases, an approach called drug repurposing. 'The idea of drug repurposing or identifying new uses for existing drugs, can speed up the drug discovery process because the compounds already have been tested for toxicity and adverse events,' Marina Sirota, PhD, professor and interim director of the University of California — San Francisco Bakar Computational Health Sciences Institute explained to Medical News Today.'Alzheimer's disease is a complex disease, which is very difficult to treat so we need to use all the tools possible to speed up drug discovery and help patients,' said SirotaSirota is the co-senior author of a new study recently published in the journal Cellthat has identified two cancer medications that may help overturn brain changes caused by Alzheimer's disease, possibly slowing or even reversing the disease's symptoms. Focusing on cancer drugs letrozole and irinotecanFor this study, researchers began by using past studies to assess how Alzheimer's disease changed gene expression in brain cells, mainly neurons and glia. 'Glia cells are non-neuronal cells that provide support and protection to neurons in the nervous system,' Sirota explained. 'By targeting both neuronal cells and non-neuronal cells (glia) we hope to be able to more comprehensively target disease pathophysiology.' From there, scientists then took the gene expression signatures they found and used a database called the ConnectivityMap, allowing them to examine thousands of drugs to find ones that reversed the Alzheimer's disease gene expression signature.'We started with a set of 1,300 drugs and narrowed it down to the combination of letrozole and irinotecan through data driven analysis using both molecular and clinical data,' Sirota said.'We first identified compounds that reversed the cell type specific disease signatures back to normal based on the gene expression profiles. We then further filtered the list to the candidates that affect several cell types,' she explained.'Then we wanted to see whether patients who are on those drugs already have a lower risk of Alzheimer's disease by querying electronic medical records across the UC system,' she continued. 'This has allowed us to narrow our list down to a handful of drugs and focus on this combination.' The analysis of electronic medical records did indeed show that both drugs were associated with a significantly lower risk of Alzheimer's disease, confirming the of cancer drugs reverses brain cell damage, reduces protein build-up in mouse modelNext, researchers decided to test the combination of letrozole — used to treat breast cancer — and irinotecan — used to treat colorectal and lung cancer — in a mouse model of aggressive Alzheimer's disease. At the study's conclusion, Sirota and her team found that the drug combination overturned multiple aspects of Alzheimer's disease in the mouse model, including undoing the gene expression signature changes in the neurons and glia caused by the disease. Additionally, researchers found the combination cancer drugs helped reduce the amount of amyloid-beta and tau proteins in the brain, which are known hallmarks of Alzheimer's disease. 'This tells us that multiple levels of evidence — molecular data, clinical information and mouse model experiments are all aligning to tell us that these compounds might be helpful for Alzheimer's disease patients,' Sirota further noted that:'While we don't know the exact mechanism of how these drugs work to treat Alzheimer's disease, we know that irinotecan is a chemotherapy drug that works by inhibiting the enzyme DNA topoisomerase I, specifically targeting the S and G2 phases of the cell cycle. Letrozole's mechanism of action involves inhibiting the enzyme aromatase, which is crucial in the biosynthesis of estrogen.''However, we don't know whether it is the main aforementioned mechanisms or off-target effects of these drugs which might help Alzheimer's disease patients,' Sirota cautioned. 'Additional experiments need to be carried out to better understand how these two drugs might work together to combat Alzheimer's disease in patients.'Using 'big data' and inventive approaches to find potential Alzheimer's drug targetsMNT had the opportunity to speak with John Dickson, MD, PhD, a neurologist at Massachusetts General Hospital, about this research. 'This is an interesting and innovative paper that uses 'big data' to aid in identifying potential drug targets to treat Alzheimer's disease and then tests candidates in a preclinical model of Alzheimer's disease,' Dickson, who was not involved in this research, said.'Combining the use of transcriptomic data from brain tissue from Alzheimer's disease patients, drug perturbation studies in cell lines, and patient data from electronic medical records was an inventive approach to identifying and narrowing down potential drug targets,' he Dickson's view, 'the decision to use a dual-therapy approach and plan to target multiple cell types with this strategy was also innovative.''The combination of drugs showed beneficial effects on the memory testing and neuropathological findings in a mouse model of Alzheimer's disease. In addition to identifying two potential candidate therapies for Alzheimer's disease, this paper also provides an experimental paradigm for identifying new drugs to treat a variety of conditions,' he look at repurposing existing drugs for Alzheimer's treatment? MNT also talked to Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA, about this study, who said it is refreshing to see data that supports improving memory loss through a novel mechanism that is not related to current therapies that work on brain acetylcholine, N-methyl-D-aspartate (NMDA), or amyloid.'This study's design is smart and the data is captivating,' Segil, who likewise was not involved in the research, added. 'Repurposing medications already being used has been extremely rewarding in neurologists and I truly hope something grows out of this research.' And Peter Gliebus, MD, neurologist and director of cognitive and behavioral neurology at Marcus Neuroscience Institute, part of Baptist Health South Florida, also not involved in the research, commented to MNT that this was a promising and exciting study, and said that repurposing existing drugs offers several advantages. 'Faster development since these drugs already have established safety profiles, which reduces the time and cost required for clinical trials,' Gliebus noted.'Cost-effectiveness [is achieved] by avoiding the high expenses associated with developing new drugs from scratch. And [this approach has] a broader impact, as many existing drugs may have unexplored mechanisms that could address complex Alzheimer's disease pathologies, such as neuroinflammation, synaptic dysfunction, and metabolic deficits.''Given the high failure rate of Alzheimer's drug trials, repurposing provides a practical and efficient pathway to identify effective treatments,' the neurologist concluded.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store